CorMedix Inc. (CRMD) Monday said the U.S. Food and Drug Administration has approved initiating a clinical study for Neutrolin in the United States.
"Neutrolin is being developed to help prevent catheter-related infections and thrombosis," said Antony Pfaffle, Chief Scientific Officer of CorMedix.
The company's investigational new drug application for Neutrolin includes a Phase 3 protocol in hemodialysis patients with a central venous catheter, CorMedix said.
CorMedix is also developing an Phase 3 protocol for Neutrolin to prevent catheter related infections in oncology patients receiving total parenteral nutrition.
For comments and feedback contact: editorial@rttnews.com
Business News